Detalhe da pesquisa
1.
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway.
Cancer Cell
; 6(1): 33-43, 2004 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15261140
2.
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Mol Cancer Ther
; 7(9): 2955-66, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18790776
3.
Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.
Bioorg Med Chem Lett
; 18(14): 4242-8, 2008 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18547806
4.
Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
Cell Cycle
; 15(5): 730-9, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26890478
5.
Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.
Neoplasia
; 14(6): 519-25, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22787433
6.
Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
Clin Cancer Res
; 17(11): 3706-15, 2011 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21482692
7.
In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.
Clin Cancer Res
; 16(7): 2076-84, 2010 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20233881
8.
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Cancer Res
; 70(12): 4972-81, 2010 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20501833